Jason Griffiths

Keywords ER+ breast cancer everolimus resistance SMARCD3 regulon growth-factor signaling transcriptomics MEK1/2 inhibitors therapeutic targeting Introduction Breast cancer (BC) remains the most common diagnosed cancer and the second leading cause of cancer-related deaths among women worldwide.1 In the United States alone, 310,720 new invasive BC cases were diagnosed in 2024, of which over 42,000 women are expected to succumb to the disease.2 The estrogen receptor-positive (ER+)/human...

Account Executive Jason will tell you that his greatest joy is helping his customers transform their technical roadblocks into real-world wins. Let’s learn more about how Jason drives customer success—and how Confluent’s one-team culture fosters seamless collaboration and better outcomes for customers. How have you grown or changed since joining Confluent? Working at Confluent has been hugely beneficial to my career in software sales.

Abstract Tumors are comprised of subpopulations of cancer cells that harbor distinct genetic profiles and phenotypes that evolve over time and during treatment. By reconstructing the course of cancer evolution, we can understand the acquisition of the malignant properties that drive tumor progression. Unfortunately, recovering the evolutionary relationships of individual cancer cells linked to their phenotypes remains a difficult challenge.